南美洲和中美洲单克隆抗体市场预测至 2028 年 - COVID-19 影响和区域分析（按来源（人、人源化、嵌合和鼠）、生产方法（体外和体内）、适应症（癌症、自身免疫性疾病） 、传染病、炎症性疾病、微生物疾病等）、应用（治疗应用、诊断应用和研究应用）、最终用户（医院、研究所等）
No. of Pages: 151 | Report Code: TIPRE00028629 | Category: Life Sciences
No. of Pages: 151 | Report Code: TIPRE00028629 | Category: Life Sciences
根据 NCBI 报告，单克隆抗体 (mAB) 已被认为是一种创新技术治疗某些类型的癌症，因为它们具有靶向和选择性杀死肿瘤细胞的能力。例如，根据巴西卫生监管机构（Anvisa）的咨询进行了一项回顾性分析，其中根据目标抗原、抗体类型、注册年份、治疗适应症和申请人对这些单克隆抗体进行了表征。据记录，2021 年 8 月，Anvisa 宣布授予 Celltrion 的“Regdanvimab (CT-P59)”紧急使用授权 (EUA)。用于治疗患有轻度至中度 COVID-19 且不需要补充氧气且进展为重症 COVID 的风险较高的成年人。由于巴西是南美洲和中美洲确诊病例数最多的国家，平均每天有 35,000 例病例，自疫情爆发以来，至少有十分之一的居民受到感染，总共报告了 20,249,176 例重症病例。因此，Celltrion 基于单克隆抗体的产品可显着降低 COVID-19 相关住院和死亡风险，对于进展为重症 COVID-19 风险较高的患者和所有患者的 70% 而言，该风险降低了 72%。因此，在 COVID-19 大流行期间，单克隆抗体在南美洲和中美洲区域市场的采用率达到了历史最高水平。
凭借新功能和技术，供应商可以吸引新客户并扩大他们在新兴市场的足迹。这一因素可能会推动单克隆抗体市场。南部和南部预计中美洲单克隆抗体市场在预测期内将以良好的复合年增长率增长。
Strategic insights for South and Central America Monoclonal Antibodies involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 5,584.2 Million |
| Market Size by 2028 | US$ 10,847.3 Million |
| Global CAGR (2021 - 2028) | 9.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 来源
|
| Regions and Countries Covered | 南美洲和中美洲
|
| Market leaders and key company profiles |
The regional scope of South and Central America Monoclonal Antibodies refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The South and Central America Monoclonal Antibodies Market is valued at US$ 5,584.2 Million in 2021, it is projected to reach US$ 10,847.3 Million by 2028.
As per our report South and Central America Monoclonal Antibodies Market, the market size is valued at US$ 5,584.2 Million in 2021, projecting it to reach US$ 10,847.3 Million by 2028. This translates to a CAGR of approximately 9.9% during the forecast period.
The South and Central America Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Monoclonal Antibodies Market report:
The South and Central America Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Monoclonal Antibodies Market
